Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy
Source abstract
Abstract
Cationic liposomes have been investigated as non-viral vectors for gene delivery for more than a decade to overcome challenges associated with viral gene delivery. However, due to instability of liposomes, siRNA delivery is still a serious problem. In this study, we developed stealth PEGylated liposome formulations and focused on the effects of PEGylated liposomes on parameters related to size, zeta potential, polydispersity index, siRNA-loading efficiency and long-term stability of the siRNA-liposome complex. We were able to generate siRNA lipoplexes that could be very efficiently loaded, did not aggregate, could be stored at 4 °C for at least 6 months with only marginal release (1-5%) of siRNA and enhanced intracellular delivery of siRNA. Moreover, we could demonstrate that PEGylation positively contributed to all these parameters compared to liposomes, which were not PEGylated. The prepared lipoplex was successfully silenced J1P1 expression in MG-63 osteosarcoma cell line. In conclusion, our novel PEGylated liposomes have high potential for systemic delivery of siRNA and can improve in vivo stability of free siRNA and also siRNA lipoplexes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran
Department of Biotechnology and Pharmaceutical Engineering, School of Chemical Engineering, College of Engineering, University of Tehran
Department of Oral and Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam
References (23)
Show source-provided references
1. 10.1007/s11095-017-2272-610.1007/s11095-017-2272-6 ↗
2. 10.3322/caac.2126210.3322/caac.21262 ↗
3. 10.1111/cbdd.1295310.1111/cbdd.12953 ↗
4. Garcia A, Jemal EM, Ward MM, et al. Global cancer facts & figures. Atlanta (GA): American Cancer Society; 2007.
5. 10.1053/j.gastro.2006.06.01610.1053/j.gastro.2006.06.016 ↗
6. 10.1016/j.ajps.2014.08.01110.1016/j.ajps.2014.08.011 ↗
7. 10.1016/j.nantod.2012.06.01310.1016/j.nantod.2012.06.013 ↗
8. 10.2217/17435889.3.6.76110.2217/17435889.3.6.761 ↗
9. 10.1039/C7RA01736G10.1039/C7RA01736G ↗
10. 10.1016/S0006-291X(02)02013-210.1016/S0006-291X(02)02013-2 ↗
11. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85:187–200.
12. 10.1016/j.ymthe.2006.01.00110.1016/j.ymthe.2006.01.001 ↗
13. 10.1038/nbt108110.1038/nbt1081 ↗
14. 10.1016/j.addr.2010.03.00810.1016/j.addr.2010.03.008 ↗
15. 10.1021/mp800134q10.1021/mp800134q ↗
16. 10.18632/oncotarget.60010.18632/oncotarget.600 ↗
17. 10.1080/21691401.2017.130440310.1080/21691401.2017.1304403 ↗
18. 10.1007/s11095-012-0874-610.1007/s11095-012-0874-6 ↗
19. 10.1007/s10856-007-3193-410.1007/s10856-007-3193-4 ↗
20. 10.1016/j.jconrel.2008.09.00310.1016/j.jconrel.2008.09.003 ↗
21. 10.1016/S0378-5173(02)00623-310.1016/S0378-5173(02)00623-3 ↗
22. 10.1016/S0168-3659(03)00230-X10.1016/S0168-3659(03)00230-X ↗
23. 10.1021/bc049743q10.1021/bc049743q ↗